1 VIDAS® TB-IGRA accuracy in tuberculosis patients and persons at varying risk of

2 exposure

3 Supplementary Information

4 Study sites

5 Site FR01

- 6 Etablissement Français du Sang (EFS), Lyon, Auvergne Rhône-Alpes, France
- 7 Yves Mérieux, Francis Camoin, Marie-Christine Lambert, Carine Marliere
- 8 Clinical Affairs laboratory, bioMérieux, Marcy l'étoile, France
- 9 Laurence Bridon, Pauline Fabre, Aurélie Langlet, Florence Senot, Isabelle Millon

10

11 Site FR02

- 12 Lariboisière Hospital, Paris, France
- 13 Dr. Amanda Lopes, Prof Emmanuelle Cambau, Dr Faiza Mougari, Prof Philippe Manivet, Claire Pernin,
- 14 Lydia Suarez, Valerie Andrianasolonirina, Véronique Delasse

15

16 **Site FR03**

- 17 Avicenne Hospital, Paris, France
- 18 Dr. Frédéric Méchaï, Fadhila Messani, Miassa Slimani, Ingrid Jacquelin. Laboratory (TB culture): Pr.
- 19 Etienne Carbonnelle, Laure Poulet

20

21 **Site FR04**

- 22 CHU de Saint-Etienne 42055 Saint-Etienne cedex 02
- Prof. Elisabeth Botelho-Nevers.
- 24 Infectious diseases: Dr Amandine Gagneux-Brunon, Dr Anne Fresard, Veronique Ronat, Philippine
- Bourrassaud, Anne Pouvaret. Pneumology: Prof Jean Michel Vergnon, Dr Marios Froudarakis, Rémi
- 26 Chapelon. Dermatology: Prof Jean Luc Perrot, Marie Chazelle. Rheumatology: Prof Hubert Marotte,
- 27 Hervé Locrelle. Occupational Medicine: Prof Luc Fontana, Marie Christine Coquet. Laboratory: Dr
- 28 Claude Lambert, Dr Anne Berger, Alice Haccourt, Alice Chanavat

29

30 Site FR05

- 31 Anti-TB center of Chambéry, Chambéry, France
- 32 Dr. Margaux Isnard, Dr Cécile Descotes-Genon, Ms Marie-Christine Carret, Mr Tarik Habet, Dr Marion
- 33 Levast, Ms Evelyne Capitan, Corinne Bernati

34

35 Site FR06

- 36 Lapeyronie Hospital, Montpellier, France
- 37 Dr. Edouard Tuaillon.
- 38 Infectious diseases: Quam Edem Aquereburu. Rheumatology: Prof Jacques Morel, Beatrice Tinland,
- 39 Sylvie Gouilloux. Occupational Medicine: Dr François-Xavier Lesage, Dr Guillaume Choron, Xavier
- 40 Loche. Laboratory: Dr Amandine Pisoni, Brigitte Burrut, Françoise Bel.

41

42 Site FR07

- 43 Anti-TB center of Nanterre, Nanterre, France
- 44 Dr. Amel Medjahed-Artebasse

46 Bacteriology laboratory, Antoine Béclère Hospital (APHP), Clamart, France

- 47 Testing of samples from sites FR03 and FR07
- 48 Pr Doucet- Populaire Florence, Dr Christelle Guillet-Caruba, Rachida Aït El Far, Sandrine Roze, Daniel
- 49 Martinho
- 50
- **51 Site GB01**
- 52 St Thomas' Hospital, London, UK
- 53 Dr. Ronan Breen, Arbane Gill, Laletha Agoramoorthy
- 54
- **55 Site GB02**
- 56 Evelina London Children's Hospital, London, UK
- 57 Dr. Julia Kenny, Dr Marc Tebruegge, Bethany Hamilton, Christian Henderson, Daniella Hydes

58

- 59 CIDR Laboratory (Centre for Clinical Infection & Diagnostics Research)
- 60 VIDAS testing for sites GB01 and GB02
- 61 Dr. Rahul Batra, Amita Patel, Bindi Patel

62

- 63 **Site IT01**
- 64 INMI L. Spallanzani, Rome, Italy
 - Dr. Delia Goletti, Dr Elisa Petruccioli, Dr Gina Gualano, Valentina Vanini, Gilda Cuzzi

65 66

- **67 Site ME01**
- 68 Autonomous University of Baja California, Mexicali, Mexico
- 69 Dr. Julia Dolores Estrada Guzman, Dr Rosa Herrera-Torres, Dr Zuceth Duran-Gomez, Dr Fernanda
- 70 Cervantes-Lopez, Dr Rene Machado-Contreras, Salvador Josaet Cervantes-Borrego, Yosef Dueñez-
- 71 Uriarte

72

- **73 Site US01**
- Rutgers University, Newark, NJ (USA)
- 75 Dr. Maria Laura Gennaro, Dr Alfred Lardizabal, Deborah Handler, Dr. Natalie Bruiners, Dr. Rahul Ukey,
- 76 Blas Peixoto, Alberta Onyuka, Ariana Alcaide

77

- 78 Collaborating hospitals with US01
- 79 Doreen Dutchak RN, and Christian Engell, MD, Newark Beth Israel Medical Center
- 80 Mabel La Forgia, RN, and Joseph DePasquale, MD, Jersey City Medical Center

81

- 82 **Site US02**
- 83 University of California San Diego, San Diego, CA (USA)
- Dr. David T. Pride, Nathan Kendrick, Steven Hendrickx, Stephanie Solso, Helene Le, Joseph Lencioni,
- 85 Rueben Barba, Maria Pizzaro, Jenny Shin

86

- 87 **Site US04**
- 88 Stanford University, Palo Alto, CA (USA)
- 89 Dr. Niaz Banaei, Arena Shafeque, Fiona Senchyna

90

- 91 **Site US05**
- 92 Saint Louis University, St Louis, MO (USA)
- 93 Dr. Daniel Hoft, Dr. Azra Blazevic, Linda Eggemeyer-Sharpe, Janice Tennant, Sabrina Dipiazza, Kate
- 94 Lierfer, Joan Siegner, Amanda Nethington, Tammy Blevins, Yinyi Yu, Huan Ning

- 96 **Site US06**
- 97 National Jewish Health, Denver, CO (USA)
- 98 Dr. Charles Daley, Dr Robert Belknap, Dr Michael Wilson, Michael Higgins, Kaylynn Aiona 99
- 100 Site US07
- 101 University of Illinois, Chicago, IL (USA)
- Dr Nahed Ismail, Dr Susan Bleasdale, Anh Nguyen, Iuliana Bentea, Brenna Lindsey
- 103 104 **Site ZA01**
- 105 University of Cape Town, Cape Town, South Africa
- 106 Prof. Keertan Dheda, Dr Aliasgar Esmail, Dr Suzette Oelofse, Dr Lynelle Mottay, Marietjie Pretorius,
- Richard Meldau, Carley Mandviwala, Maria Gorgel, Eleanor Pretorius, Solomri Foloti, Lusanda Yenani,
- 108 Vonnita Loren, Wasiela Galant
- 109
- 110 Site **ZA02**
- 111 TASK Applied Science, Cape Town, South Africa
- 112 Dr Naadira Vanker, Dr Caryn Upton, Michelle Eriksson, Martha Jacobs, Anastacia Arendse, Wendy
- Wakens, Dorothy Zakariya, Alexandra Waltman, Chantell Meyer, Margaret Muller, Michele van Rooyen,
- Phumza Setlaba, Patricia Maunder, Mlungisi Mnunu, Doreen Petersen, Charné Rossouw, Magdalene
- Kennedy, Silvia Nunes, Thirumani Govender, Lize Greyling, Jacqueline Russouw, Katriena Ross, Tracy
- Jack, Kurt McQuire, Diane Lavies, Beulah Classen, Carmen Kleinhans, Julia Sims, Bryan Esterhuizen,
- 117 Sven Friedrich, Cebisa Mdladla, Bongiwe Gwadela, Fay Swanson, Pascal Musoni, Dustin Bosch, Lucille
- October, Atica Moosa, Karabo Mahlangu, Olwethu Ngxishe, Chaldene Johannes, Chantal Botha, Alta
- 119 Mwela, Levlani Croy
- 120 121
- 122 Supplementary Methods
- 123 Sensitivity of QFT-Plus and VIDAS® TB-IGRA were independently calculated, as follows:

Sensitivity =
$$100 * \frac{TP}{TP + FN}$$

- where TP = true positives (i.e., culture-confirmed TB disease and positive test result) and
- FN = false negatives (*i.e.*, culture-confirmed TB disease and negative test result).
- 127
- To evaluate the VIDAS® TB-IGRA accuracy for the mixed exposure risk population, positive
- percent agreement (PPA) and negative percent agreement (NPA) relative to the QFT-Plus were
- calculated as follows, along with the 95% confidence interval (95%CI).

131
$$PPA = 100 * \frac{a}{a+c} \quad and \quad NPA = 100 * \frac{d}{d+b}$$

where a, b, c, and d are defined as follows:

		QFT-Pl			
		Positive	Negative	Total	
VIDAS®	Positive	a	b	a+b	
TB-IGRA result	Negative	С	d	c+d	
	Total	a+c	b+d	a+b+c+d	

Supplementary Tables and Figures

135

136

Supplementary Table S1. Study sites for the TB disease and mixed exposure risk populations.

Region	Country	Site Code	Site name / City	Principal Investigator Site responsibilities		TB disease Patients (n = 200)	Mixed exposure risk Participants (n = 1460)
EU	France	FR01*	Clinical Affairs Laboratory, bioMérieux / Marcy l'Etoile	Laurence Bridon	Laurence Bridon VIDAS testing		125
EU	France	FR02	Lariboisière Hospital / Paris	Dr. Amanda Lopes	Recruitment, Testing (QFT-Plus and VIDAS)	5	-
EU	France	FR03**	Avicenne Hospital / Paris	Dr. Frederic Méchaï	Recruitment	3	2
EU	France	FR04	North Hospital / St. Etienne	Prof. Elisabeth Botelho- Nevers	Recruitment, Testing (QFT-Plus and VIDAS)	4	91
EU	France	FR05	Anti-TB center of Chambéry	Dr. Margaux Isnard	Recruitment, Testing (QFT-Plus and VIDAS)	5	45
EU	France	FR06	Lapeyronie Hospital / Montpellier	Dr. Edouard Tuaillon	Recruitment, Testing (QFT-Plus and VIDAS)	_	86
EU	France	FR07**	Anti-TB center of Nanterre	Dr. Amel Medjahed	Recruitment	_	127
EU	UK	GB01***	St Thomas' Hospital / London	Dr. Ronan Breen	Recruitment	1	11
EU	UK	GB02***	Evelina London Children's Hospital	Dr. Marc Tebruegge replaced by Dr Julia Kenny	Recruitment	_	3
EU	Italy	IT01	INMI L. Spallanzani-IRCCS / Rome	Dr. Delia Goletti	Recruitment, Testing (QFT-Plus and VIDAS)	5	28
US	USA	US01	Rutgers University / Newark	Dr. Maria Laura Gennaro	Recruitment, Testing (QFT-Plus and VIDAS)	17	77
US	USA	US02	University of California / San Diego	Dr. David T. Pride	Recruitment, Testing (QFT-Plus and VIDAS)	-	5
US	USA	US04	Stanford University / Palo Alto	Dr. Niaz Banaei	Recruitment, Testing (QFT-Plus and VIDAS)	-	144
US	USA	US05	Saint Louis University	Dr. Daniel Hoft	Recruitment, Testing (QFT-Plus and VIDAS)	_	207
US	USA	US06	National Jewish Health / Denver	Dr. Charles Daley	Recruitment, Testing (QFT-Plus and VIDAS)	_	100

US	USA	US07	University of Illinois / Chicago	Dr Nahed Ismail	Recruitment, Testing (QFT-Plus and VIDAS)	-	179
ROW	Mexico	ME01	Autonomous University of Baja California / Mexicali	Dr. Julia Dolores Estrada Guzman	Recruitment, Testing (QFT-Plus and VIDAS)	3	77
ROW	South Africa	ZA01	University of Cape Town	Prof. Keertan Dheda	Recruitment, Testing (QFT-Plus and VIDAS)	105	74
ROW	South Africa	ZA02	TASK Applied Science / Cape Town	Dr. Naadira Vanker	Recruitment, Testing (QFT-Plus and VIDAS)	52	79

^{*} For the additional responsibilities:

138

139

142

143

- Recruitment was performed by the national French organization for blood donation (EFS) Auvergne Rhône-Alpes
- QFT®-Plus testing was performed by St Etienne Hospital (site FR04 laboratory)
- ** Testing (QFT-Plus and VIDAS) was performed by Antoine Béclère Hospital (APHP), Bacteriology laboratory, Clamart, France
- 141 *** For the additional responsibilities:
 - QFT-Plus testing was performed by TDL Trials The Doctors Laboratory
 - VIDAS testing was performed by CIDR (Centre for Clinical Infection & Diagnostics Research) Guy's and St Thomas' NHS Foundation Trust, London
- Abbreviations: EU, European Union; ROW, Rest of the World; US, United States.

Supplementary Table S2. Criteria for stratification of the mixed exposure risk population based on TB-exposure risk level.

Number of **TB-exposure risk** Criteria individuals (%) Extremely Blood donors from low burden countries, 125 (8.6%) Low without known TB-exposure risk factors Persons without known TB-exposure risk Aggregate 333 Very Low who were screened for TB infection prior to 90 (6.2%) Low (22.8%)or during immunosuppressive therapy Medical students in low TB-burden countries 118 (8.1%) Low without known TB-exposure risk factors Healthcare workers or volunteers without 598 Medium Low known TB-exposure risk factors (41.0%)Persons from TB-related settings in low TB-Medium 13 (0.9%) burden countries Aggregate 679 Medium (46.5%) Immigrants or residents of countries with high TB incidence Medium High 68 (4.7%) Persons who spent >1 month in an area with high TB incidence 296 High TB-case contacts (non-household) (20.3%)Aggregate 447 Very High TB-case contacts (same house) 81 (5.6%) High (30.6%) Extremely 70 (4.8%) TB-case contacts (same bedroom) High

146

147

Supplementary Table S3. Institutional Review board (IRB) or Independent Ethics Committee (IEC) approval codes for each study operating site. All sites complied with the Declaration of Helsinki, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) guidelines as applicable to *in vitro* diagnostic (IVD) studies, and the laws and regulations of their respective countries. The Principal Investigator of each site was responsible for ensuring compliance with these regulations and adherence to approved protocols, and written informed consent was obtained from all study participants.

Site Code	Country	IRB/IEC Code		
FR01	France	N/A (French Blood Bank)		
FR02 FR03 FR04 FR05 FR06 FR07	France	2019-A00998-49		
GB01 GB02	UK	CTPR01 IRAS: 265866; REC: 19/WA/0284 CTPR02 IRAS: 266217; REC: 19/WA/0285 REC: Wales REC 7		
IT01	Italy	INMI "L. Spallanzani" Ethics Committee approval n°35/2019		
ME01	Mexico	02-01-HGMXL/FMED-UABC-2019-08-29-254		
US01	USA	CTPR01: Pro2019001840; CTPR02: Pro2019001936		
US02 US05 US06	USA	WIRB Tracking Number CTPR01: 20191965; CTPR02: 20192037; CTPR03: 20192039		
US04	USA	eProtocol#: 53485		
US07	USA	2019-1145		
ZA02	South Africa	Pharma ethics CTPR01: 190822774; CTPR02: 190822777 SAHPRA CTPR01: MD20190803; CTPR02: MD20190804 University of Cape Town Human Research Ethics Committee CTPR01 and 2: 840/2019		

Abbreviations: IRAS, Integrated Research Application System; SAHPRA, South African Health

150

151

152

153

154

155

156

¹⁵⁹ Products Regulatory Authority; REC, Research Ethics Committee; WIRB, Western Institutional Review

¹⁶⁰ Board.

Supplementary Table S4. Cut-off values and result interpretation for the VIDAS® TB-IGRA assay.

NIL (IU/ml)	AG-NIL (IU/ml)			Clinical Significance		
	≥ 0.35 and ≥25% NIL	Any	Positive	M. tb infection likely		
< 6.40	< 0.35	≥ 1.1	Negative	M. tb infection not likely		
	or ≥ 0.35 and < 25% NIL	< 1.1	INDETERMINATE MIT Low	Likelihood of <i>M. tb</i> infection cannot be determined		
≥ 6.40	Any		INDETERMINATE NIL High	Likelihood of <i>M. tb</i> infection cannot be determined		

Abbreviations: AG, antigen; MIT, mitogen (positive control); NIL, negative control.

163

Supplementary Table S5. Negative percent agreement (NPA) and positive percent agreement (PPA) for the VIDAS[®] TB-IGRA relative to the QFT-Plus test for individuals in the mixed exposure risk population at nine levels of risk for TB, ranging from extremely low to extremely high. NPA and PPA were also calculated for the three main levels of TB exposure: aggregate low, medium, and high.

	QFT-Plus Negative results (n=1217)				QFT-Plus Positive results (n=242)			
TB-Exposure Risk	n	VIDAS® TB- IGRA		NPA	n	VIDAS® TB- IGRA		PPA
		Neg.	Pos.	[95%CI]		Pos.	Neg.	[95%CI]
Extremely Low	119	119	0	100% [96.9, 100.0]%	6	3	3	50.0% [18.8, 81.2]%
Very Low	84	78	6	92.9% [85.3, 96.7]%	6	4	2	66.7% [30.0, 90.3]%
Low	117	113	4	96.6% [91.5, 99.1]%	1	1	0	100.0% [2.5, 100.0]%
Aggregate Low	320	310	10	96.9% [94.3, 98.5]%	13	8	5	61.5% [35.5, 82.3]%
Medium Low	593	550	43	92.7% [90.4, 94.6]%	5	2	3	40.0% [11.8, 76.9]%
Medium	13	12	1	92.3% [66.7, 98.6]%	0	N/A	N/A	N/A
Medium High	31	25	6	80.6% [63.7, 90.8]%	37	34	3	91.9% [78.7, 97.2]%
Aggregate Medium	637	587	50	92.2% [89.8, 94.0]%	42	36	6	85.7% [72.2, 93.3]%
High	184	144	40	78.3% [71.8, 83.6]%	112	104	8	92.9% [86.5, 96.3]%
Very High	45	36	9	80.0% [66.2, 89.1]%	36	36	0	100.0% [90.3, 100.0]%
Extremely High	31	20	11	64.5% [46.9, 78.9]%	39	39	0	100.0% [91.0, 100.0]%
Aggregate High	260	200	60	76.9% [71.4, 81.6]%	187	179	8	95.7% [91.7, 98.1]%

 ${\bf Abbreviations}{:}\ CI,\ confidence\ interval;\ QFT-Plus,\ QuantiFERON\ Plus.$

165

166

167

168




173 174

175176

177178

179


180



Active TB: 200* Mixed Risk: 1460

- 76 patients with negative TB-culture
- 55 patients with positive TB-culture due to sequential design


Supplementary Figure S1. Flow of participants through the study.



Supplementary Figure S2. Distribution of interferon (IFN)- γ concentrations measured by the QFT-Plus and VIDAS® TB-IGRA in the mixed exposure risk population. The dashed line, at 0.35 IU/mL, represents the cut-off that is used for result interpretation. For the VIDAS® TB-


^{*} patients not included in sensitivity computations:

IGRA, the cut-off applies to antigen (AG)-negative control (NIL) value. For the QFT-Plus, the cut-off applies to TB1-NIL and TB2-NIL values. See supplementary table S4 for more details about the VIDAS® TB-IGRA interpretation algorithm. Values from concordant results were spread across the measuring interval for both tests, as follows: i) from 0 to 0.35 IU/mL for concordant negative results (blue boxes on left side of the graph) and ii) from 0.35 IU/mL to the end of the respective measuring interval of each assay, for concordant positive results (blue boxes on right side of the graph). For discrepant results with QFT®-Plus positive (red boxes in green bands), TB1-NIL and TB2-NIL values were grouped more tightly near the cut-off relative to the positive concordant results. In contrast, when the VIDAS® TB-IGRA was positive (red box in yellow band), AG-NIL values covered a large portion of the measuring interval, with several points in the higher half. This suggests that at least a portion of discrepant results were associated with IFN- γ concentrations far from the cut-off, especially when the VIDAS® TB-IGRA was positive.



Supplementary Figure S3. Univariate and multivariate odds ratios determined by logistic regression for aggregate TB exposure risk groups.





Supplementary Figure S4. Univariate and multivariate odds ratios determined by logistic regression for the three subgroups in the aggregate-high TB exposure risk group.